Neuroprotective effect of nipradilol [3,4-dihydro-8-(2-hydroxy-3- isopropylamino)-propoxy-3-nitroxy-2H-1-benzopyran] in a rat model of optic nerve degeneration

Journal of Glaucoma

Volumn 18, Issue 1, 2009, Pages 26-31

  Karim, Md Zahidul ^a   Sawada, Akira ^a   Mizuno, Ken ^b   Kawakami, Hideaki ^a   Ishida, Kyoko ^a   Yamamoto, Tetsuya ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOWA COMPANY LTD   (Japan)

Author keywords

Neuroprotection; Nipradilol; Nitric oxide; Optic nerve; Retinal ganglion cells

Indexed keywords

NIPRADILOL; ANTIHYPERTENSIVE AGENT; NEUROPROTECTIVE AGENT; PROPANOLAMINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL DENSITY; CELL LABELING; CELL SURVIVAL; CONTROL GROUP; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; HISTOPATHOLOGY; INTRAOCULAR PRESSURE; MALE; NEUROPROTECTION; NONHUMAN; OPTIC NERVE INJURY; PRIORITY JOURNAL; RAT; RETINA; RETINA GANGLION CELL; RETINA INJURY; SHAM PROCEDURE; SUPERIOR COLLICULUS; SURVIVAL RATE; WISTAR RAT; ANIMAL; CELL COUNT; NERVE DEGENERATION; PATHOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL COUNT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; INTRAOCULAR PRESSURE; MALE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; OPTIC NERVE INJURIES; PROPANOLAMINES; RATS; RATS, WISTAR; RETINAL GANGLION CELLS;

EID: 63449131868     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181752c6f     Document Type: Article

References (45)

1. Adachi K, Kashii S, Masai H, et al. Mechanism of pathogenesis of glutamate neurotoxicity in retinal ischemia. Graefes Arch Clin Exp Ophthalmol. 1998;23:766-774.
2. Neufeld AH. Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Surv Ophthalmol. 1999;43: S129-S135.
3. McKinnon SJ. Glaucoma, apoptosis, and neuroprotection. Curr Opin Ophthalmol. 1997;8:28-37.
4. Armaly MF, Krueger DE, Maunder L, et al. Biostatistical analysis of the collaborative glaucoma study. 1. Summary report of the risk factors for glaucomatous visual-field defect. Arch Ophthalmol. 1980;98:2163-2171.
5. Brubaker RF. Delayed functional loss in glaucoma. L11 Edward Jackson Memorial Lecture. Am J Ophthalmol. 1996; 121:473-483.
6. Osborne NN, Chidlow G, Nash MS, et al. The potential of neuro-protection in glaucoma treatment. Curr Opin Ophthalmol. 1999; 10:82-92.
7. Chierzi S, Fawcett JW. Regeneration in the mammalian optic nerve. Restor Neurol Neurosci. 2001;19:109-118.
8. Uchida Y, Nakamura M, Shimuzu S, et al. Vasoactive and beta-adrenoceptor blocking properties of 3,4-dihydro-8-(2-hydroxy-3-isopropylamino)-propoxy-3- nitroxy-2H-1 benzopyran (k-351), a new antihypertensive agent. Arch Int Pharmacodyn Ther. 1983;262:132-149.
9. Ohira T, Wada Y, Fujii M, et al. Effects of nipradilol (k-351) on alpha-adrenoceptor mediated responses in various isolated tissues. Arch Int Pharmacodyn Ther. 1985;278:61-71.
10. Okumura T, Kitamura Y, Uchiyama M, et al. Canine retinal arterial and arteriolar dilatation induced by nipradilol, a possible glaucoma therapeutic. Pharmacology. 1996;53: 302-310.
11. Masuda K, Takase M, Kitazawa Y, et al. Phase 111 comparative clinical study on KT-210 in patients with primary open-angle glaucoma and ocular hypertension: multicenter cooperative between-group comparative double-blind clinical trial with 0.5% timolol maleate ophthalmic solution. J Eye. 1996;13:1771-1783.
12. Furuta Y, Matuoka A, Sano H, et al. Effect of nipradilol on ambulatory blood pressure of essential hypertensive patients. Ther Res. 1994;15:379-385.
13. Scriabine A, Torchiana ML, Stavorski JM, et al. Some cardiovascular effects of timolol, a new beta-adrenergic blocking agent. Arch Int Pharmacodyn Ther. 1973;205:76-93.
14. Kanno M, Araie M, Tomita K, et al. Effects of topical nipradilol, a β blocking agent with α blocking and nitroglycerin-like activities, on aqueous humor dynamics and fundus circulation. Invest Ophthalmol Vis Sci. 1998;39:736-743.
15. Kanno M, Araie M, Kobuchi H, et al. Effects of topical nipradilol, a β blocking agent with α blocking and nitrogly-cerin-like activities, on intraocular pressure and aqueous dynamics in humans. Br J Ophthamol. 2000;84:293-299.
16. Mizuno K, Koide T, Yoshimura M, et al. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci. 2001;42:688-694.
17. Snyder SH, Bredt DS. Biological roles of nitric oxide. Sci Am. 1992;266:68-77.
18. Bredt DS, Snyder SH. Nitric oxide, a novel neuronal messenger. Neuron. 1992;8:3-11.
19. Goldstein IM, Ostwald P, Roth S. Nitric oxide: a review of its role in retinal function and disease. Vis Res. 1996;36: 2979-2994.
20. McMahan DG, Ponomareva LV. Nitric oxide and cGMP modulate retinal glutamate receptors. J Neurophysiol. 1996;76: 2307-2315.
21. Vorwerk CK, Hyman BT, Miller JW, et al. The role of neuronal and endothelial nitric oxide synthase in retinal excitotoxicity. Invest Ophthalmol Vis Sci. 1997;38:2038-2044.
22. Neufeld AH, Sawada A, Backer B. Inhibition of nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci USA. 1999;96:9944-9948.
23. Kim YM, Chung HT, Kim SS, et al. Nitric oxide protects PC12 cells from serum deprivation-induced apoptosis by cGMP-dependent inhibition of caspase signaling. J Neurosci. 1999;19:6740-6747.
24. Levkovitch-Verbin H, Quigley HA, Martin KR, et al. A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. Invest Ophthalmol Vis Sci. 2003;44: 3388-3393.
25. Honjo M, Tanihara H, Kido N, et al. Expression of ciliary neurotrophic factor activated by retinal Muller cells in eyes with NMDA- and kainic acid-induced neuronal death. Invest Ophthalmol Vis Sci. 2000;41:552-560.
26. Moore P, El-Sherbeny A, Roon P, et al. Apoptotic cell death in the mouse retinal ganglion cell layer is induced in vivo by the excitatory amino acid homocysteine. Exp Eye Res. 2001;73: 45-57.
27. Morizane C, Adachi K, Furutani I, et al. Nω-nitro-L-arginine methyl ester protects retinal neurons against N-Methyl-D-aspartate-induced neurotoxicity in vivo. Eur J Pharmacol. 1997;328:45.
28. Perry VH. Evidence for an amacrine cell system in the ganglion cell layer of the rat retina. Neuroscience. 1981;6:931-944.
29. Sisk DR, Kuwabara T. Histologic changes in the inner retina of albino rats following intravitreal injection of monosodium L-glutamate. Graefes Arch Clin Exp Ophthalmol. 1985;223: 250-258.
30. Siliprandi R, Canella R, Carmignoto G, et al. N-methyl-D-aspartate induced neurotoxicity in the adult rat retina. Vis Neurosci. 1992;8:567-573.
31. Dreyer EB, Pan ZH, Storm S, et al. Greater sensitivity of larger retinal ganglion cells to NMDA-mediated cell death. Neuroreport. 1994;5:629-631.
32. Sawada A, Neufeld AH. Confirmation of the rat model of chronic, moderately elevated intraocular pressure. Exp Eye Res. 1999;69:525-531.
33. Yoles E, Schwartz M. Degeneration of spared axons following partial white matter lesion: implications for optic nerve neuropathies. Exp Neurol. 1998;153:1-7.
34. Gellrich NC, Schimming R, Zerfowski M, et al. Quantification of histological changes after calibrated crush of the intraorbital optic nerve in rats. Br J Ophthalmol. 2002;6:233-237.
35. Adachi K, Fujita Y, Morizane C, et al. Inhibition of NMDA receptors and nitric oxide synthase reduces ischemic injury of the retina. Eur J Pharmacol. 1998;350:53-57.
36. Kapin MA, Doshi R, Scatton B, et al. Neuroprotective effects of eliprodil in retinal excitotoxicity and ischemia. Invest Ophthalmol Vis Sci. 1999;40:1177-1182.
37. Lagreze WA, Knorle R, Bach M, et al. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest Ophthalmol Vis Sci. 1998;39:1063-1066.
38. Brandstatter JH, Hartveit E, Sassoe-Pognetto M, et al. Expression of NMDA and high affinity kainite receptor sub-unit mRNAs in the adult rat retina. Eur J Neurosci. 1994;6: 1100-1112.
39. Lipton SA, Choi YB, Sucher NJ, et al. Neuroprotective versus neurodestructive effects of NO-related species. Biofactors. 1998;8:33-40.
40. Yoshitomi T, Yamaji K, Ishikawa H, et al. Vasodilatory effects of nipradilol, an alpha- and beta-adrenergic blocker with nitric oxide releasing action, in rabbit ciliary artery. Exp Eye Res. 2002; 75:669-676.
41. Nakazawa T, Tomita H, Yamaguchi K, et al. Neuroprotective effect of nipradilol on axotomized rat retinal ganglion cells. Curr Eye Res. 2002;24:114-122.
42. Arend O, Harries A, Arend S, et al. The acute effect of topical beta-adrenoreceptor blocking agents on retinal and optic nerve head circulation. Acta Ophthalmol Scand. 1998;76:43-49.
43. Adachi T, Hori S, Miyazaki K, et al. Rapid increase in plasma nitrite concentration following intravenous administration of nipradilol. Eur J Pharmacol. 1995;286:201-204.
44. Goto W, Ota T, Morikawa N, et al. Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res. 2002;958:10-19.
45. Kida T, Suguyama T, Harino S, et al. The effect of nipradilol, an alpha-beta blocker, on retinal blood flow in healthy volunteers. Curr Eye Res. 2001;23:128-132.